|Bid||0.2850 x N/A|
|Ask||0.2950 x N/A|
|Day's Range||0.2900 - 0.3000|
|52 Week Range||0.1000 - 0.3500|
|Beta (5Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If you're interested in Sernova Corp. (CVE:SVA), then you might want to consider its beta (a measure of share price...
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
LONDON and ONTARIO , California , Oct. 24, 2019 /CNW/ -- Sernova Corp. (SVA.V) (SEOVF) (PSH.F), a clinical-stage regenerative medicine company, is pleased to announce that Mr. David Swetlow , CPA, CA, has joined Sernova as Chief Financial Officer. Adding a full-time CFO at this inflection point for the company with our recent announcement of initial positive early efficacy indicators for our Cell Pouch(TM) Phase I/II US clinical trial for type-1 diabetes and ongoing business development activities will accelerate execution of the company's financial, business and capital markets goals and strategies," said Dr. Philip Toleikis , President and CEO of Sernova. Sernova's outgoing CFO, Mr. Sean Hodgins , will assist with the transition as he continues to provide contract CFO services to his technology company clients.